Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
A
A

Amgen

Balita

Reuters - 8 oras ang nakaraan

Amid an uncertain landscape, high quality may offer stable ground

LIVE MARKETS-Amid an uncertain landscape, high quality may offer stable ground Dow and S&P 500 climb, Nasdaq off ~0.2% Financials lead S&P 500 sector gainers; Comm Svcs weakest group Euro STOXX 600 index up ~0.5% Dollar slips; gold, crude both off ~1%; bitcoin off >2% U.S. 10-Year Treasury yield dips to ~3.82% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
G
K
N
V
G
U
U
F
I
S
U
A
G
B
Reuters - 1 araw ang nakaraan

Amgen sues Samsung biotech unit over bone drug copies

Amgen sues Samsung biotech unit over bone drug copies By Blake Brittain Aug 13 (Reuters) - Amgen AMGN.O has sued Samsung's biologics unit 207940.KS in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster bone drugs Prolia and Xgeva. Amgen's lawsuit against Samsung Bioepis, filed on Monday, said the biosimilars would infringe 34 patents covering Amgen drugs.
A
Reuters - 6 araw ang nakaraan

Amgen To Open New Site In Hyderabad, India

BRIEF-Amgen To Open New Site In Hyderabad, India Aug 9 (Reuters) - Amgen Inc AMGN.O : AMGEN TO OPEN NEW SITE IN HYDERABAD, INDIA Source text for Eikon: ID:nPreCsdBha Further company coverage: AMGN.O
A
Reuters - 1 linggo ang nakaraan

Tech surge, BOJ's dovish comments boost Wall Street

US STOCKS-Tech surge, BOJ's dovish comments boost Wall Street For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Airbnb slides after forecasting Q3 revenue below estimates Fortinet jumps on FY revenue forecast raise Charles River slides after cutting FY forecasts Indexes up: S&P 500 1.36%, Nasdaq 1.64%, Dow 0.9% Updated at 11:22 a.m.
A
A
T
U
U
U
U
D
Reuters - 1 linggo ang nakaraan

U.S. STOCKS Abbott Laboratories, Medtronic, Axon

BUZZ-U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes advanced on Wednesday, aided by a dovish turn by Japan's top policymaker after a surprise interest rate hike last week which partly sparked heavy volatility in global markets.
A
A
C
F
I
T
U
U
L
Reuters - 1 linggo ang nakaraan

Wall St charges ahead as Big Tech relief rally continues

US STOCKS-Wall St charges ahead as Big Tech relief rally continues For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Airbnb slides after forecasting Q3 revenue below estimates Fortinet jumps after raising FY revenue forecast Charles River slides after cutting FY forecasts Indexes up: S&P 500 1.2%, Nasdaq 1.7%, Dow 0.7% Updated at 9:35 a.m.
A
A
N
U
U
U
U
D
Reuters - 1 linggo ang nakaraan

U.S. STOCKS Ralph Lauren, Illumina, Disney

BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures jumped on Wednesday as risk appetite returned after a steep selloff earlier in the week, and cautious comments on interest-rate hikes by an influential Bank of Japan policymaker.
A
C
F
I
T
U
G
L
S
A
Reuters - 1 linggo ang nakaraan

Wall St set to open higher as Big Tech buying continues

US STOCKS-Wall St set to open higher as Big Tech buying continues For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Airbnb slides after forecasting Q3 revenue below estimates Fortinet jumps after raising FY revenue forecast CVS Health down after cutting FY profit forecast Futures up: S&P 500 1%, Nasdaq 1.18%, Dow 0.72% Updated at 8:25 a.m.
A
A
M
N
U
W
U
U
U
D
Reuters - 1 linggo ang nakaraan

U.S. STOCKS Walt Disney, SpringWorks, Shopify

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures jumped on Wednesday as risk appetite returned after a steep selloff earlier in the week, with sentiment also getting a boost from cautious comments on interest-rate hikes by an influential Bank of Japan policymaker.
A
F
T
U
L
S
Reuters - 1 linggo ang nakaraan

Futures advance as Big Tech continues to recover

US STOCKS-Futures advance as Big Tech continues to recover For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Airbnb slides after forecasting Q3 revenue below estimates Fortinet jumps after raising FY revenue forecast CVS Health down after cutting FY profit forecast Futures up: Dow 0.8%, S&P 1.2%, Nasdaq 1.5% Updated at 7:05 a.m.
A
A
M
N
U
W
U
U
U
D
Reuters - 1 linggo ang nakaraan

Futures rally as Big Tech extends recovery

US STOCKS-Futures rally as Big Tech extends recovery For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Futures up: S&P 500 1.05%, Nasdaq 1.21%, Dow 0.79% Aug 7 (Reuters) - U.S. stock index futures jumped on Wednesday as risk appetite returned after a steep selloff earlier in the week, with sentiment also getting a boost from cautious comments on interest-rate hikes by an influential Bank of Japan policymaker.
A
B
U
U
U
U
D
A
Reuters - 1 linggo ang nakaraan

Amgen falls as Q2 profit slips

BUZZ-Amgen falls as Q2 profit slips ** Drugmaker Amgen's AMGN.O shares fall 4% to $315.51 premarket ** Co late on Tuesday reported Q2 adjusted profit of $4.97 per share, largely in-line with average analyst estimate -LSEG data ** Adj. profit slipped 1% year-over-year hurt by higher expenses, including costs related to development of its experimenta
A
Reuters - 1 linggo ang nakaraan

U.S. Amgen, Atkore, MoneyLion

U.S. RESEARCH ROUNDUP-Amgen, Atkore, MoneyLion Aug 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen, Atkore and MoneyLion on Wednesday. HIGHLIGHTS * Amgen Inc AMGN.O : RBC raises target price to $362 from $332 * Atkore Inc ATKR.N : RBC cuts to sector perform from outperform * MoneyLion ML.N : Needham cuts target price to $70 from $100 * Progyny Inc PGNY.O : BTIG cuts to neutral from buy * Truecar Inc TRUE.O :
A
A
A
B
B
Reuters - 1 linggo ang nakaraan

Amgen Inc reports results for the quarter ended in June - Earnings Summary

Amgen Inc reports results for the quarter ended in June - Earnings Summary Amgen Inc AMGN.OQ reported quarterly adjusted earnings of $4.97​​ per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of $5.00. The mean expectation of twenty two analysts for the quarter was for earnings of $5.01 per share.
A
Reuters - 1 linggo ang nakaraan

Amgen falls on downbeat second-quarter profit

BUZZ-Amgen falls on downbeat second-quarter profit ** Shares of drugmaker Amgen AMGN.O fall ~1.8% to $322.99 in after-market trade ** AMGN reports Q2 adj. profit of $4.97/shr vs analysts' average est. of $5/shr - LSEG ** Says quarterly profit slipped 1% due to higher expenses ** Company's quarterly revenue of $8.39 bln beats analysts' average expectation of $8.37 bln ** AMGN raises the lower end of its 2024 revenue outlook to a range of $32.8 bln to $33.8 bln from a previous low end forecast of
A
Reuters - 1 linggo ang nakaraan

Amgen quarterly profit slips, obesity data on track for late 2024

UPDATE 2-Amgen quarterly profit slips, obesity data on track for late 2024 Adds analyst comment paragraph 4, company comment paragraph 10; updates share price By Deena Beasley Aug 6 (Reuters) - Amgen AMGN.O on Tuesday said its second-quarter profit slipped 1% as higher expenses, including costs related to development of its experimental obesity drug MariTide, offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
A
Reuters - 1 linggo ang nakaraan

Amgen second quarter profit dips, sales rise 20%

Amgen second quarter profit dips, sales rise 20% By Deena Beasley Aug 6 (Reuters) - Amgen AMGN.O on Tuesday said its second-quarter profit slipped 1% as higher expenses offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics. Amgen reported adjusted earnings of $4.97 per share, which was just short of the average analyst estimate of $5.00, according to LSEG data.
A
Reuters - 1 linggo ang nakaraan

U.S. STOCKS IDEXX, Amgen, Airbnb

BUZZ-U.S. STOCKS ON THE MOVE-IDEXX, Amgen, Airbnb Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
I
U
U
F
M
R
U
V
M
Reuters - 1 linggo ang nakaraan

PREVIEW: Amgen shares climb with results on tap

BUZZ-PREVIEW: Amgen shares climb with results on tap ** Amgen AMGN.O shares up 1.8% at $331.09 ahead of Q2 results due after the closing bell amid broad market recovery from three-day selloff ** The biotech company is expected to post EPS of $5.01 on revenue of $8.33 bln, per LSEG data, vs yr-ago results of $5.00 in EPS and $6.99 bln in revenue **
A
U
Reuters - 1 linggo ang nakaraan

Rollercoaster markets, Nikkei rebounds 10%

MORNING BID AMERICAS-Rollercoaster markets, Nikkei rebounds 10% A look at the day ahead in U.S. and global markets from Mike Dolan The speed and scale of Tuesday's 10% Tokyo bounce after its worst day in 37 years suggests the wild global market swings of the past week are more rooted in speculative churn than economic fright. While that's only partly reassuring - as persistent market turbulence can itself sap economic activity - there's good reason to believe a slowing U.S.
A
C
N
U
W
J
U
U
U
F
F
D
I
J
M
S
B

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.